NextCell Pharma publishes its Interim Report 2 2024/2025

April 25, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second Quarter (2024-12-01 to 2025-02-28)

Operating income amounted to 3,417 (2,405) TSEK, of which Cellaviva contributed 3,248 (2,334) TSEK.
Net sales amounted to 3,248 (2,334) TSEK.
Profit/loss after financial items amounted to -8,198 (-10,093) TSEK.
Earnings per share* were -0.11 (-0.29) SEK.
Cash and cash equivalents amounted to 26,338 (30,393) TSEK.
Equity ratio** amounted to 83 (79) percent.

First Half Year (2024-09-01 to 2025-02-28)

Operating income amounted to 6,281 (7,099) TSEK, of which Cellaviva contributed 6,077 (6,580) TSEK.
Net sales amounted to 6,077 (6,580) TSEK.
Profit/loss after financial items amounted to -16,240 (-19,889) TSEK.
Earnings per share* were -0.40 (-0.58) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first half year of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 28 February 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the second quarter

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from theProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," comment- ed Mathias Svahn, CEO.
Mid Februari NextCell announced that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, had been treated.

Significant events after the reporting period

At the end of March NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr Lindsay Davies had been elected to the board of ATMP Sweden.

In the beginning of April NextCell Pharma announced preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo.
NextCell Pharma announced early April that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, had been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT).
Mid April NextCell Pharma published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discussed with Mathias Svahn questions regarding the latest results from ProTrans-YOUNG.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
RedEye AB is assigned as Certified Adviser.
The company's shares are listed on the Nasdaq First North Growth Market.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2025-05-16

The exercise period for NextCell Pharma’s warrants of series TO2 begins today

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (“NextCell” or the “Company”) issued a total of 38,711,804 warrants of series TO2 (“Warrants”) within the framework of a rights issue of units during the second quarter of 2025. The exercise period for the Warrants commences today, on May 16, 2025, and continues until May 30, 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company. The subscription price per share subscribed for through the exercise of Warrants has been set at SEK 1.00. Upon full utilization of all Warrants, NextCell will receive approximately SEK 38.7 million before issuance costs. The proceeds from the exercise of Warrants are mainly intended to support the completion of the ProTrans-Young study and continued clinical development, business development, and regulatory preparations for future market approval.

Read more Read more

2025-05-15

Eight-Year-Old Hugo – Living with Type 1 Diabetes and Participating in the ProTrans Study

NextCell Pharma AB ("NextCell") is featured in the Future Healthcare – Focus on Diabetes supplement of the Swedish national newspaper Svenska Dagbladet, through an article highlighting eight-year-old Hugo Wahlbeck, who is currently enrolled in the ongoing paediatric study with ProTrans – the Company’s leading investigational therapy for the treatment of type 1 diabetes.

Read more Read more

2025-05-07

Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell

NextCell Pharma AB (“NextCell” or the “Company”) highlights a recently published clinical trial demonstrating promising results for mesenchymal stromal cells (MSCs) in the treatment of mild Alzheimer’s disease. The results strengthen the scientific foundation for NextCell’s drug candidate ProTrans, which is being developed for autoimmune and inflammatory diseases. NextCell is developing the next generation of MSC therapies with a focus on selection and indication-specific tailoring using its patented platform technology.

Read more Read more

2025-04-25

NextCell Pharma publishes its Interim Report 2 2024/2025

Read more Read more

2025-04-24

NextCell presents detailed analysis of the administrative report from ProTrans-Young

NextCell Pharma AB’s ("NextCell" or "the Company") CSO, Lindsay Davies, has been interviewed by Flemingsberg Science regarding the analysis of the administrative topline evaluation from the older age cohort of the ProTrans-Young paediatric trial.

Read more Read more

2025-04-23

NextCell Presents Quarterly Report

NextCell Pharma AB ("NextCell" or the "Company") invites investors, analysts and media to an investor presentation in conjunction with the publication of the Company's second interim report for the 2024/2025 financial year, on Thursday, 25 April 2025.

Read more Read more

2025-04-15

NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward

NextCell Pharma (“the company” or “NextCell”) has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the latest results from ProTrans-YOUNG and NextCell's participation at the International Diabetes Congress in Bangkok 7-10 April. The interview is now available with English subtitles on NextCell's website https://www.nextcellpharma.com/nyheter#foretagspresentationer

Read more Read more

2025-04-09

NextCell’s CSO elected Vice President Elect for ISCT Europe

NextCell Pharma AB ("NextCell") announces that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT). The role is a key position within the organisation’s global leadership, offering significant influence over the future direction of cell and gene therapies, both across Europe and internationally.

Read more Read more